Univariate and multivariate Cox regression analyses of survival of the Epo-G (n = 123) and the selected IPSS/IMRAW (n = 334) cohorts together
. | Total no. . | No. dead . | Unadjusted odds . | 95% CI . | P . | Adjusted odds . | 95% CI . | P . |
|---|---|---|---|---|---|---|---|---|
| Cohort | ||||||||
| IPSS/IMRAW | 334 | 217 | Ref | — | — | Ref | — | — |
| Epo-G | 123 | 99 | 0.9 | 0.7-1.2 | .56 | 0.9 | 0.7-1.2 | .55 |
| No. of cytopenias | ||||||||
| 0 or 1 | 196 | 114 | Ref | — | — | Ref | — | — |
| 2 or 3 | 261 | 202 | 2.2 | 1.7-2.7 | <.001 | 1.6 | 1.5-2.4 | <.001 |
| Karyotype* | ||||||||
| Good | 300 | 189 | Ref | — | — | Ref | — | — |
| Intermediate | 68 | 47 | 1.3 | 0.9-1.8 | .11 | 1.2 | 0.9-1.7 | .23 |
| Poor | 81 | 73 | 2.8 | 2.1-3.7 | <.001 | 2.4 | 1.8-3.2 | <.001 |
| Unknown | 8 | 7 | 1.4 | 0.7-3.0 | .38 | 0.7 | 0.3-1.6 | .45 |
| BM blasts | ||||||||
| Less than 5% | 277 | 161 | Ref | — | — | Ref | — | — |
| 5% to 10% | 121 | 105 | 2.2 | 1.8-2.9 | <.001 | 1.9 | 1.5-2.5 | <.001 |
| 11% to 20% | 59 | 50 | 3.6 | 2.6-4.9 | <.001 | 3.1 | 2.1-4.4 | <.001 |
| Age | ||||||||
| 16 to 45 y | 19 | 8 | Ref | — | — | Ref | — | — |
| 46 to 55 y | 50 | 26 | 1.0 | 0.5-2.2 | .99 | 1.4 | 0.6-3.1 | .42 |
| 56 to 65 y | 95 | 65 | 1.6 | 0.8-3.3 | .23 | 1.8 | 0.8-3.7 | .13 |
| 66 to 75 y | 133 | 92 | 1.7 | 0.8-3.6 | .14 | 2.1 | 1.0-4.4 | .04 |
| 76 to 85 y | 135 | 104 | 2.3 | 1.1-4.7 | .02 | 3.2 | 1.5-6.6 | .002 |
| More than 85 y | 25 | 21 | 3.1 | 1.4-7.1 | .01 | 3.5 | 1.5-7.9 | .003 |
| Sex | ||||||||
| Male | 255 | 190 | Ref | — | — | Ref | — | — |
| Female | 202 | 126 | 0.7 | 0.6-0.9 | .002 | 0.7 | 0.6-0.9 | .01 |
| Study | ||||||||
| Non-Epo-G study III | 405 | 280 | Ref | — | — | Ref | — | — |
| Epo-G study III | 52 | 36 | 0.8 | 0.6-1.2 | .28 | 1.0 | 0.7-1.5 | .99 |
. | Total no. . | No. dead . | Unadjusted odds . | 95% CI . | P . | Adjusted odds . | 95% CI . | P . |
|---|---|---|---|---|---|---|---|---|
| Cohort | ||||||||
| IPSS/IMRAW | 334 | 217 | Ref | — | — | Ref | — | — |
| Epo-G | 123 | 99 | 0.9 | 0.7-1.2 | .56 | 0.9 | 0.7-1.2 | .55 |
| No. of cytopenias | ||||||||
| 0 or 1 | 196 | 114 | Ref | — | — | Ref | — | — |
| 2 or 3 | 261 | 202 | 2.2 | 1.7-2.7 | <.001 | 1.6 | 1.5-2.4 | <.001 |
| Karyotype* | ||||||||
| Good | 300 | 189 | Ref | — | — | Ref | — | — |
| Intermediate | 68 | 47 | 1.3 | 0.9-1.8 | .11 | 1.2 | 0.9-1.7 | .23 |
| Poor | 81 | 73 | 2.8 | 2.1-3.7 | <.001 | 2.4 | 1.8-3.2 | <.001 |
| Unknown | 8 | 7 | 1.4 | 0.7-3.0 | .38 | 0.7 | 0.3-1.6 | .45 |
| BM blasts | ||||||||
| Less than 5% | 277 | 161 | Ref | — | — | Ref | — | — |
| 5% to 10% | 121 | 105 | 2.2 | 1.8-2.9 | <.001 | 1.9 | 1.5-2.5 | <.001 |
| 11% to 20% | 59 | 50 | 3.6 | 2.6-4.9 | <.001 | 3.1 | 2.1-4.4 | <.001 |
| Age | ||||||||
| 16 to 45 y | 19 | 8 | Ref | — | — | Ref | — | — |
| 46 to 55 y | 50 | 26 | 1.0 | 0.5-2.2 | .99 | 1.4 | 0.6-3.1 | .42 |
| 56 to 65 y | 95 | 65 | 1.6 | 0.8-3.3 | .23 | 1.8 | 0.8-3.7 | .13 |
| 66 to 75 y | 133 | 92 | 1.7 | 0.8-3.6 | .14 | 2.1 | 1.0-4.4 | .04 |
| 76 to 85 y | 135 | 104 | 2.3 | 1.1-4.7 | .02 | 3.2 | 1.5-6.6 | .002 |
| More than 85 y | 25 | 21 | 3.1 | 1.4-7.1 | .01 | 3.5 | 1.5-7.9 | .003 |
| Sex | ||||||||
| Male | 255 | 190 | Ref | — | — | Ref | — | — |
| Female | 202 | 126 | 0.7 | 0.6-0.9 | .002 | 0.7 | 0.6-0.9 | .01 |
| Study | ||||||||
| Non-Epo-G study III | 405 | 280 | Ref | — | — | Ref | — | — |
| Epo-G study III | 52 | 36 | 0.8 | 0.6-1.2 | .28 | 1.0 | 0.7-1.5 | .99 |
Ref indicates reference category.
Karyotype categories good, intermediate, and poor according to the IPSS.